



Genocea Biosciences
Investor Relations Department
100 Acom Park Drive, 5th Floor
Cambridge, MA 02140
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: GNCA


Last Trade:	1.46
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.13 - 7.29
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 25, 2017*
[Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines](#)
- Sep 20, 2017*
[Genocea to Present at Cantor Fitzgerald Healthcare Conference](#)
- Aug 9, 2017*
[Genocea Biosciences Reports Second Quarter 2017 Financial Results](#)
- Jul 28, 2017*
[Genocea Biosciences to Highlight GEN-003 Clinical Data at the 42nd Annual International Herpesvirus Workshop](#)
- Jul 24, 2017*
[Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 17, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)